Sona Nanotech Announces Collaboration with Leading Diagnostic Company to Improve Performance of Foodborne Pathogen Tests

Halifax, Nova Scotia–(Newsfile Corp. – March 7, 2019) – Sona Nanotech Inc. (CSE: SONA) today announced a collaboration with global diagnostics solutions provider Romer Labs to improve performance in their RapidChek® SELECT™ pathogen test kits.

With over 30 years of experience in this field, and labs in Austria, UK, US and Singapore, Romer Labs is a leading provider of diagnostic solutions for the agricultural, food and feed industry.

Romer Labs uses lateral flow assay technology across multiple product lines including its RapidChek® SELECT™ and AgraStrip® test strips that detect foodborne pathogens, mycotoxins, food allergens, GMOs and meat and bone meal (MBM) in animal feed.

The companies are positive Sona’s unique gold nanorods will increase the performance of Romer’s RapidChek® SELECT™ product lines and have agreed to work collaboratively to achieve this goal.


Mark Muldoon (L), Director, R&D for Romer Labs and Darren Rowles (R), CEO of Sona Nanotech

Sona CEO Darren Rowles said:”We are excited to be collaborating with Romer Labs, which shows our continued ambition of working with market-leading, high-growth, innovative companies in their sector. Romer Labs is a pioneering business at the forefront of diagnostic technology that produces millions of lateral flow strips annually, has laboratories across the world and continues to build a growing and diverse portfolio of high-quality products for the food and agricultural sectors. With our combined technologies I am certain we can produce tests that improve on the sensitivity and performance of those currently on the market and increases Sona’s reach into valuable new markets related to the food and agriculture industries.”

Michael Prinster, CEO of Romer Labs said: “We are excited about the potential of this collaboration. Our key objective at Romer Labs is to provide scientifically sound, high-quality products and an exceptional service. We are constantly expanding our product and service portfolio to meet the continuously evolving needs of our customers. We are confident Sona Nanotech’s unique gold nanotechnology will help increase the performance of our RapidChek® SELECT™ products, improving our offering to new and existing customers.”

Unsafe food causes serious global health threats as well as placing a huge burden on public health systems across the world. In 2015 a report by the World Health Organisation (WHO) estimated the burden of foodborne diseases caused by 31 agents – bacteria, viruses, parasites, toxins and chemicals. It found that each year as many as 600 million people, or almost 1 in 10 people in the world, fall ill after consuming contaminated food. Of these, 420,000 people die, including 125,000 children under the age of five. [1]

Consumers are becoming more aware of the risks of foodborne pathogens and are increasingly demanding better quality and safety in the food they eat, and so the demand for foodborne pathogen testing is increasing. In 2017 the global food safety testing market was valued at $13.14 billion, and is estimated to reach $23.20 billion by 2025, registering a compound annual growth rate (CAGR) of 7.3% from 2018 to 2025. [2]

[1] https://www.who.int/foodsafety/areas_work/foodborne-diseases/ferg/en/

[2] https://www.foodsafetystrategies.com/articles/453-study-pathogen-testing-to-lead-global-food-safety-testing-market-by-2025

About Sona Nanotech Inc.

Sona Nanotech Inc. is a nanotechnology life sciences firm that has developed two proprietary methods for the manufacture of rod-shaped gold nanoparticles. The principal business carried out and intended to be continued by Sona is the development and application of its proprietary technology for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market.

Sona’s gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, pending the approval of various regulatory boards including Health Canada and the FDA.

Sona is a publicly listed company on the Canadian Securities Exchange existing under the laws of Nova Scotia, with its operations in Nova Scotia.

About Romer Labs

Founded in Washington, MO, in 1982, Romer Labs has become a leading provider of diagnostic solutions for the agricultural, food and feed industry.

Today, Romer Labs offers a broad range of innovative diagnostic solutions covering mycotoxins, food pathogens, food allergens, gluten, GMO, veterinary drug residues, and other food contaminants.

It operates four accredited, full-service laboratories in Austria, UK, US and Singapore. Using cutting-edge technology in the fields of chromatography and immunological analysis, its labs offer services for the analysis of mycotoxins, food allergens, meat speciation, VDR and GMO.

Romer Labs is at the forefront of diagnostic technology. Its mission statement is: “Making the World’s Food Safer®”

For More Information

For more information about Sona, please contact:

Darren Rowles
President and Chief Executive Officer
Telephone: (902) 442-7192
Email: Darren Rowles darren@sonanano.com

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements and information that are based on the beliefs of management and reflect the Company’s current expectations. When used in this press release, the words “estimate”, “project”, “belief”, “anticipate”, “intend”, “expect”, “plan”, “predict”, “may” or “should” and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. The forward-looking statements and information in this press release includes information relating to the Amalgamation (including the structure of the Amalgamation), the Amalgamation (including shareholder approval, shareholder support, and other terms), the Private Placement (including its completion and the use of proceeds from the Private Placement), the directors and management of the resulting issuer upon completion of the Amalgamation, and the implementation of Sona’s business plan. Such statements and information reflect the current view of the Company with respect to risks and uncertainties that may cause actual results to differ materially from those contemplated in those forward-looking statements and information.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: risks associated with the completion of the Amalgamation and matters relating thereto; and risks associated with the marketing and sale of securities, the need for additional financing, reliance on key personnel, the potential for conflicts of interest among certain officers or directors, and the volatility of the Company’s common share price and volume. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Investors are cautioned against attributing undue certainty to forward-looking statements.

There are a number of important factors that could cause the Company’s actual results to differ materially from those indicated or implied by forward-looking statements and information. Such factors include, among others, risks related to Sona’s proposed business, such as failure of the business strategy and government regulation; risks related to Sona’s operations, such as additional financing requirements and access to capital, reliance on key and qualified personnel, insurance, competition, intellectual property and reliable supply chains; risks related to Sona and its business generally, such as infringement of intellectual property rights and conflicts of interest. The Company cautions that the foregoing list of material factors is not exhaustive. When relying on the Company’s forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. The Company has assumed a certain progression, which may not be realized. It has also assumed that the material factors referred to in the previous paragraph will not cause such forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. While the Company may elect to, it does not undertake to update this information at any particular time.

THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS PRESS RELEASE REPRESENTS THE EXPECTATIONS OF THE COMPANY AS OF THE DATE OF THIS PRESS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE THE COMPANY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
OR DISSEMINATION IN THE UNITED STATES

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>